|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
PAI-1 has been shown to play a role in a number of diverse pathologies including cardiovascular diseases, obesity and cancer and is therefore an attractive therapeutic target.
|
30733557 |
2019 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
As inflammation is also known to occur in perirenal AT during obesity, we hypothesized that in a high-fat diet (HFD)-induced obese mouse model, PAI-1 contributes to macrophage-mediated inflammation and diabetic nephropathy.
|
30532990 |
2019 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Plasminogen activator inhibitor type-1 (PAI-1; encoded by the SERPINE1 gene), a u-PA inhibitor and antifibrinolytic agent, is often elevated in obesity and is linked to cardiovascular events.
|
31054988 |
2019 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
PAI-1 concentrations are elevated in obesity, type 2 diabetes and metabolic syndrome (MetS).
|
31023101 |
2019 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
As inflammation is also known to occur in AT during obesity, we hypothesized that in a high-fat diet (HFD)-induced obese mouse model PAI-1 contributes to macrophage-mediated inflammation and metabolic dysfunction.
|
30319420 |
2018 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Also, women with central obesity had higher circulatory PAI-1 and leptin concentrations than their non-obese counterparts.
|
29636702 |
2018 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
The significant correlations between PAI-1 levels and lipoprotein subfractions indicate the link between PAI-1 and lipid metabolism in obesity.
|
30002679 |
2018 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
These associations persisted after exclusion of factors that increase PAI-1 including tobacco exposure and obesity.
|
28543872 |
2017 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
These evidences indicate the complicated interaction between PAI-1 and obesity.
|
28378106 |
2017 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Obesity and type 2 diabetes (T2D) are associated with a suppression of fibrinolysis and an increased risk of intravascular thrombi because of elevated plasma plasminogen activator inhibitor 1 (PAI-1).
|
27387691 |
2017 |
|
Obesity
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Plasma PAI-1 antigen and activity levels are associated with increased body mass index and with features of the insulin resistance syndrome like obesity and diabetes.
|
28605281 |
2017 |
|
Obesity
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The plasma PAI-1 levels may be determined by the degree of obesity and TG metabolic disorders.
|
28692480 |
2017 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Plasminogen activator inhibitor-1 (PAI-1), a major inhibitor of fibrinolysis, is associated with thrombosis, obesity, insulin resistance, dyslipidemia, and premature aging, which all are coexisting conditions of chronic obstructive pulmonary disease (COPD).
|
28356730 |
2017 |
|
Obesity
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Increased plasma plasminogen activator inhibitor-1 (PAI-1) level is considered a mechanistic pathway through which obesity contributes to increased cardiovascular disease risk.
|
27233154 |
2016 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Leptin links with plasminogen activator inhibitor-1 in human obesity: the SABPA study.
|
25740294 |
2015 |
|
Obesity
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
This study aims to evaluate mediastinal PAI-1 and TNF-α mRNA levels in adipose tissues (AT) and compare serum levels in obesity with and without coronary artery disease (CAD).
|
26884864 |
2015 |
|
Obesity
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To assess whether the -675 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene is associated with obesity and insulin resistance in Mexican children.
|
23871496 |
2014 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
CTD_human |
Together, resveratrol can act as NF κ B inhibitor in adipocytes and thus the subsequently reduced PAI-1 expression in inflamed adipose tissue might provide a new insight towards novel treatment options of obesity.
|
23819014 |
2013 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
In the present study, we aimed to determine whether hypoxia induces S1P in adipocytes, thereby potentially contributing to an increase in PAI-1 and hence constraints on fibrinolysis associated with obesity.
|
24212262 |
2013 |
|
Obesity
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Together, resveratrol can act as NF κ B inhibitor in adipocytes and thus the subsequently reduced PAI-1 expression in inflamed adipose tissue might provide a new insight towards novel treatment options of obesity.
|
23819014 |
2013 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Moreover, reciprocal expression between miR-30c and PAI-1 could also be demonstrated in white adipose tissue of obesity mouse models, suggesting a potential physiological role of miR-30c for PAI-1 regulation in the obese state.
|
21878751 |
2013 |
|
Obesity
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The -675 4G/5G PAI-1 and the -308 TNF-α polymorphism variants tested in this study, individually or combined, were not associated with obesity in an Argentinean population.
|
22106856 |
2012 |
|
Obesity
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Intrapair differences in fibrinogen and PAI-1 correlated with those in BMI, adiposity, and fasting insulin levels (r = 0.40-0.58, P < 0.05) indicating the independent effect of obesity.
|
21959347 |
2012 |
|
Obesity
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Adipose tissue is a suggested source of the elevated plasma levels of PAI-1 in obesity.
|
22740034 |
2012 |
|
Obesity
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Vitamin D has also been implicated in asthma through its effects on the obesity, bacillus Calmettee Guérin (BCG) vaccination and high vitamin D level, vitamin D supplement, checkpoint protein kinase 1 (Chk1), plasminogen activator inhibitor-1 (PAI-1) and gamma delta T cells (gdT).
|
22532985 |
2012 |